Breo Ellipta (Fluticasone furoate/Vilanterol) for asthma | MyAsthmaTeam

Connect with others who understand.

sign up Log in
About MyAsthmaTeam
Powered By

Breo Ellipta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for daily maintenance treatment of asthma in people 18 or older. Breo Ellipta helps prevent bronchospasms. Breo Ellipta cannot be used as a rescue inhaler for sudden breathing problems.

Breo Ellipta is a combination drug containing both Fluticasone furoate and Vilanterol. Fluticasone furoate is a glucocorticoid steroid, a drug that suppresses the immune system. Fluticasone furoate is believed to work by reducing inflammation in the lungs, lowering the risk of bronchospasm. Vilanterol is a long-acting bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Vilanterol is believed to work by relaxing smooth muscles in the airways.

How do I take it?
Take one inhalation of Breo Ellipta once a day. Breo Ellipta should be taken at the same time each day.

Breo Ellipta comes as an inhalation powder in two separate blister packs, with an inhaler.

Side effects
The FDA-approved label for Breo Ellipta lists common side effects including runny nose, headache, oral yeast infection, influenza, sinus infection, bronchitis, throat pain, cough, and difficulty speaking.

Rare but serious side effects include problems with the adrenal glands, heart problems, glaucoma, decreased bone density, fungal infections, hypersensitivity reactions, and paradoxical bronchospasm (bronchospasm caused by taking medication).

For more details about this treatment, visit:
Breo Ellipta — GSK

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of use and Privacy policy.
Already a Member? Log in